Syschem (India) Limited

BSE:531173 Stock Report

Market Cap: ₹1.6b

Syschem (India) Past Earnings Performance

Past criteria checks 2/6

Syschem (India) has been growing earnings at an average annual rate of 43.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 25.3% per year. Syschem (India)'s return on equity is 2.1%, and it has net margins of 0.4%.

Key information

43.9%

Earnings growth rate

40.7%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate25.3%
Return on equity2.1%
Net Margin0.4%
Next Earnings Update08 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Syschem (India) makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:531173 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242,85412700
31 Mar 242,33528640
31 Dec 232,02434600
30 Sep 231,85553550
30 Jun 231,64555500
31 Mar 231,30645470
31 Dec 2296166460
30 Sep 2272535460
30 Jun 226245430
31 Mar 22657-17490
31 Dec 21667-68500
30 Sep 21758-74500
30 Jun 21823-67440
31 Mar 21744-56450
31 Dec 20742-35390
30 Sep 20717-35340
30 Jun 20811-23330
31 Mar 20881-19330
31 Dec 19954-18330
30 Sep 19900-1310
30 Jun 199503300
31 Mar 191,0978330
31 Dec 181,18021330
30 Sep 181,23921290
30 Jun 181,01213250
31 Mar 187663290
31 Dec 174542200
30 Sep 17321-11190
30 Jun 17214-13110
31 Mar 17135-1580
31 Dec 169-510
30 Sep 1610-2120
30 Jun 168-2000
31 Mar 1636-2230
31 Dec 1599-1930
30 Sep 15105-1450
30 Jun 15115-2860
31 Mar 15114-3970
31 Dec 14101-53130
30 Sep 14136-37150
30 Jun 14170-17130
31 Mar 141846200
31 Dec 131938290

Quality Earnings: 531173 has high quality earnings.

Growing Profit Margin: 531173's current net profit margins (0.4%) are lower than last year (3.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 531173 has become profitable over the past 5 years, growing earnings by 43.9% per year.

Accelerating Growth: 531173's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 531173 had negative earnings growth (-77.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.1%).


Return on Equity

High ROE: 531173's Return on Equity (2.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies